What top creators are saying about aTyr Pharma, Inc.(ATYR)

The speaker has a very bearish outlook, stating that the company 'cannot recover.'

The speaker is bullish on this biotech stock, noting that a rumored deal has finally been announced.

The speaker had a successful, high-risk, event-driven long position that he has now completely sold. There is no longer an active investment thesis.

The host is extremely bearish due to the Phase 3 study failing its primary endpoint, refers to it as a 'scam company', holds a short position, and suggests the stock should be trading at $0.50.

A speaker expressed extreme skepticism, alleging signs of data manipulation in prior trials and calling the data 'fugazi,' suggesting the upcoming Phase 3 results are highly risky and a potential short opportunity.

The speaker is 'all in' on a short position, expecting the stock to fall to ~$0.80 from its current ~$5.54 price upon the release of what they are highly confident will be negative Phase 3 trial data.

The speaker believes the company's upcoming Phase 3 clinical trial has a 0% probability of success due to a lack of scientific mechanism, an irrelevant drug target, and weak prior clinical data, making it a clear short opportunity.

The speaker has an extremely bearish, high-conviction short thesis, believing the stock is headed towards zero due to an upcoming clinical data release expected to be poor around mid-September.

The speaker has an extremely bearish view and a high-conviction short idea, predicting the stock will go to zero soon.

The speaker has a high-conviction short thesis, believing the company's lead drug 'does not work' due to a flawed scientific hypothesis, a failed precedent drug, and weak data.

The speaker holds a 60% portfolio position in this stock, indicating extreme conviction.

The speaker is extremely bearish, holding it as his largest short position. He believes the drug has a '0% chance' of succeeding in its mid-September trial due to a lack of a plausible mechanism of action. He views a recent capital raise as a major red flag.

Bearish sentiment; the speaker calls the stock a 'zero' and holds it as a short position.

High-conviction short idea, with the speaker calling it a 'fake company' and stating a lack of faith in both its scientific foundation and its management's expertise in the pharmaceutical industry.

Speaker is extremely bearish with a significant short position, believing the lead drug is 'fake' and the stock could lose 90% of its value ahead of Phase 3 trial data expected in late August.

Extremely bearish based on a detailed critique of the company's science, which is called a 'scientific atrocity' with 'embarrassing' results, indicating a deeply flawed foundation.

This is a high-conviction short (9 or 10 out of 10), described as a 'fake drug, fake everything.' The speaker anticipates the Phase 3 data in the next 4-6 weeks will fail, causing the stock to drop significantly.

The company faces a high-risk 'binary event.' The speaker is leaning bearish due to skepticism about the validity of its clinical trial data, calling it 'noise.'

Mixed and unclear sentiment. The speaker first says 'I'm all over it' but later lists it as a potential short candidate, making the view contradictory.